PP-053 Evaluation of 5 compounded formulations for the treatment of oral mucositis in cancer patients

    loading  Checking for direct PDF access through Ovid



Oral mucositis (OM) is a frequent complication of chemotherapy which severely affects patient quality of life. Management is generally based on topical compounded formulations.


To analyse the use of our compounded formulation of Lidollanten 1% for the treatment of OM in a tertiary hospital, to describe this and four other formulations and to perform a comparative cost analysis without including professional fees.

Material and methods

We performed a 1 year retrospective study (January 2015–December 2015) involving all cancer patients who had used our compounded formulation during the study period. Patient data were obtained from the SAP application.


During the study period, we dispensed 3122 Lidollanten 1% preparations for 530 patients. The cost of preparation in the hospital was €1.55/100 mL, which meant €4 823.51/year. Different formulations for the treatment of OM are shown in the table.


According to our data, the least expensive formulation (from the point of view of acquisition cost) was No 2, which also happened to be that requiring the least processing time; it can be stored at room temperature, with an expiry time of 1 month. For these reasons, we believe it is the most efficient. Future studies will determine whether there are differences in effectiveness between the different formulations.

References and/or acknowledgements

1. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer2014;120:1453–61.

References and/or acknowledgements

No conflict of interest

Related Topics

    loading  Loading Related Articles